4 completed, 2 unknown, 1 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Unknown 2, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow ImmuneMed, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug) Burfiralimab, SOC (Standard of care), Placebo - Moderate to Severe Rheumatoid Arthritis | Phase 2 | Unknown | ImmuneMed, Inc. | 60 | 2024-03-01 | 2024-03-12 |
| A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) Standard of care - Chronic Hepatitis B | Phase 2 | Unknown | ImmuneMed, Inc. | 32 | 2022-01-11 | 2023-06-15 |
| Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Terminated | ImmuneMed, Inc. | 1 | 2021-03-18 | 2024-02-15 |
| Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Completed | ImmuneMed, Inc. | 63 | 2020-12-17 | 2024-02-15 |
| Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia hzVSF-v13, Placebo (Normal saline solution) - COVID-19 | Phase 2 | Completed | ImmuneMed, Inc. | 115 | 2020-12-11 | 2021-12-01 |
| Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration) hzVSF-v13 (intravenous, single dose), hzVSF-v13 (subcutaneous, single dose), hzVSF-v13 (intravenous, multiple dose) - Healthy Volunteers | Phase 1 | Completed | ImmuneMed, Inc. | 72 | 2020-09-16 | 2024-02-15 |
| Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers hzVSF-v13, Placebo - Healthy | Phase 1 | Completed | ImmuneMed, Inc. | 56 | 2018-11-20 | 2021-04-27 |
COVID-19 (3) · Arthritis, Rheumatoid (1) · Hepatitis B, Chronic (1)
Saline Solution (5) · Standard of Care (2) · Injections, Subcutaneous (1)
South Korea (3) · Australia (1) · Indonesia (1) · Italy (1) · Netherlands (1) · Russia (1)
Davide Sonnino, phD (1) · In-Jin Jang, M.D (1) · Jacob M. van Laar, MD (1) · Joon Hyeok Lee, M.D. Ph.D. (1) · Prasenohadi Prasenohadi, phD (1)